{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:04:36Z","timestamp":1774533876973,"version":"3.50.1"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Humans with type 2 diabetes and\/or metabolic dysfunction-associated steatotic liver disease (MASLD) are at higher risk of ST-segment elevation myocardial infarction (STEMI) and worse prognosis. However, mechanisms, prognostic factors and risk subtypes in humans with STEMI and (pre)diabetes with or without MASLD, are not fully understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The DIabetes and ST-segment Elevation Myocardial Infarction (\n                      <jats:italic>DISTEMI<\/jats:italic>\n                      ) study is a prospective longitudinal cohort study, recruiting humans with different degrees of glucose tolerance after recent STEMI. This cohort study has the primary objective to detect changes in glycemia and insulin sensitivity derived from the oral glucose tolerance test (OGTT) and their relationships to cardiac function. Secondary objectives address tissue-specific insulin sensitivity and organ function, focusing on adipose tissue, liver and heart. Exploratory objectives comprise multiomic analyses and measures of mitochondrial function and quality of life. At 2 and 12\u00a0months after STEMI, participants undergo comprehensive cardiometabolic phenotyping (OGTT, modified Botnia clamp-test, magnetic resonance imaging\/spectroscopy\/elastography, high-resolution respirometry). Magnetic resonance-based techniques are employed to assess cardiovascular function and structure, adipose tissue distribution, skeletal muscle and hepatic lipid deposition and fibrosis, and hepatic energy metabolism. Exploratory analyses include multiomics of blood, urine, and stool samples. Multiomics analyses shall allow detecting biomarkers for stratification of cardiovascular disease risk. Currently, 100 participants have been included in\n                      <jats:italic>DISTEMI<\/jats:italic>\n                      , of whom 29% have type 2 diabetes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:italic>DISTEMI<\/jats:italic>\n                      study integrates comprehensive cardiometabolic phenomic with multiomic profiling to identify cardiometabolic STEMI subtypes and predictors of outcomes, and to improve precision risk stratification and targeted prevention.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT05046483<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-026-03097-0","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:45:13Z","timestamp":1773366313000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cohort profile: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) Study"],"prefix":"10.1186","volume":"25","author":[{"given":"Clara","family":"M\u00f6ser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsiaryna","family":"Prystupa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna","family":"Yurchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K\u00e1lm\u00e1n B.","family":"B\u00f3dis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Huttasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Michelotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuliya","family":"Kupriyanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Schrauwen-Hinderling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare","family":"Granata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gidon J.","family":"B\u00f6nhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Strom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Herder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"D\u00f6rr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Trenkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geronimo","family":"Heilmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Bobrov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Stra\u00dfburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Szendroedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mareike","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin","family":"Polzin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malte","family":"Kelm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Burkart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Roden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana-Patricia","family":"Zaharia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"25","key":"3097_CR1","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","volume":"82","author":"GA Mensah","year":"2023","unstructured":"Mensah GA, et al. Global burden of cardiovascular diseases and risks, 1990\u20132022. J Am Coll Cardiol. 2023;82(25):2350\u2013473.","journal-title":"J Am Coll Cardiol"},{"issue":"41","key":"3097_CR2","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1093\/eurheartj\/ehx515","volume":"38","author":"K Szummer","year":"2017","unstructured":"Szummer K, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995\u20132014. Eur Heart J. 2017;38(41):3056\u201365.","journal-title":"Eur Heart J"},{"issue":"7","key":"3097_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633\u201344.","journal-title":"N Engl J Med"},{"issue":"14","key":"3097_CR4","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.jacc.2021.02.030","volume":"77","author":"I Cavallari","year":"2021","unstructured":"Cavallari I, et al. Causes and risk factors for death in diabetes: a competing-risk analysis from the SAVOR-TIMI 53 trial. J Am Coll Cardiol. 2021;77(14):1837\u201340.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3097_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547\u201354.","journal-title":"Hepatology"},{"issue":"7","key":"3097_CR6","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.298.7.765","volume":"298","author":"SM Donahoe","year":"2007","unstructured":"Donahoe SM, et al. Diabetes and mortality following acute coronary syndromes. JAMA. 2007;298(7):765\u201375.","journal-title":"JAMA"},{"key":"3097_CR7","doi-asserted-by":"publisher","first-page":"155800","DOI":"10.1016\/j.metabol.2024.155800","volume":"153","author":"H Choe","year":"2024","unstructured":"Choe H, et al. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up. Metabolism. 2024;153:155800.","journal-title":"Metabolism"},{"issue":"9","key":"3097_CR8","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","volume":"71","author":"TG Simon","year":"2022","unstructured":"Simon TG, et al. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut. 2022;71(9):1867\u201375.","journal-title":"Gut"},{"issue":"5","key":"3097_CR9","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/hep.32519","volume":"76","author":"Y Shang","year":"2022","unstructured":"Shang Y, et al. Risk of cardiovascular disease and loss in life expectancy in NAFLD. Hepatology. 2022;76(5):1495\u2013505.","journal-title":"Hepatology"},{"issue":"7785","key":"3097_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41586-019-1797-8","volume":"576","author":"M Roden","year":"2019","unstructured":"Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019;576(7785):51\u201360.","journal-title":"Nature"},{"issue":"12","key":"3097_CR11","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.2337\/db18-0449","volume":"67","author":"T Jelenik","year":"2018","unstructured":"Jelenik T, et al. Insulin resistance and vulnerability to cardiac ischemia. Diabetes. 2018;67(12):2695\u2013702.","journal-title":"Diabetes"},{"issue":"6","key":"3097_CR12","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams LA, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138\u201353.","journal-title":"Gut"},{"issue":"5","key":"3097_CR13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00125-006-0190-y","volume":"49","author":"C Herder","year":"2006","unstructured":"Herder C, et al. Chemokines as risk factors for type 2 diabetes: results from the MONICA\/KORA Augsburg study, 1984\u20132002. Diabetologia. 2006;49(5):921\u20139.","journal-title":"Diabetologia"},{"issue":"12","key":"3097_CR14","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.2337\/dc11-2263","volume":"35","author":"AG Tabak","year":"2012","unstructured":"Tabak AG, et al. Adiponectin trajectories before type 2 diabetes diagnosis: Whitehall II study. Diabetes Care. 2012;35(12):2540\u20137.","journal-title":"Diabetes Care"},{"issue":"1","key":"3097_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41572-025-00635-0","volume":"11","author":"R Unnikrishnan","year":"2025","unstructured":"Unnikrishnan R, et al. Prediabetes. Nat Rev Dis Primers. 2025;11(1):49.","journal-title":"Nat Rev Dis Primers"},{"issue":"34","key":"3097_CR16","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227\u2013337.","journal-title":"Eur Heart J"},{"issue":"8","key":"3097_CR17","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/CIR.0000000000001303","volume":"151","author":"SS Martin","year":"2025","unstructured":"Martin SS, et al. 2025 heart disease and stroke statistics: a report of US and global data from the american heart association. Circulation. 2025;151(8):e41\u2013660.","journal-title":"Circulation"},{"issue":"9438","key":"3097_CR18","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937\u201352.","journal-title":"Lancet"},{"issue":"21","key":"3097_CR19","doi-asserted-by":"publisher","first-page":"e013296","DOI":"10.1161\/JAHA.119.013296","volume":"8","author":"ST Vernon","year":"2019","unstructured":"Vernon ST, et al. ST-segment-elevation myocardial infarction (STEMI) patients without standard modifiable cardiovascular risk factors-how common are they, and what are their outcomes? J Am Heart Assoc. 2019;8(21):e013296.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"3097_CR20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","volume":"18","author":"G Targher","year":"2021","unstructured":"Targher G, et al. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18(9):599\u2013612.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"3097_CR21","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1161\/ATVBAHA.113.301585","volume":"33","author":"W Karrowni","year":"2013","unstructured":"Karrowni W, et al. Insulin resistance is associated with significant clinical atherosclerosis in nondiabetic patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2013;33(9):2245\u201351.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"27","key":"3097_CR22","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1093\/eurheartj\/ehac223","volume":"43","author":"S Frantz","year":"2022","unstructured":"Frantz S, et al. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur Heart J. 2022;43(27):2549\u201361.","journal-title":"Eur Heart J"},{"key":"3097_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-13-73","author":"D Trifunovic","year":"2014","unstructured":"Trifunovic D, et al. Acute insulin resistance in ST-segment elevation myocardial infarction in non-diabetic patients is associated with incomplete myocardial reperfusion and impaired coronary microcirculatory function. Cardiovasc Diabetol. 2014;13:73.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"3097_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","volume":"6","author":"E Ahlqvist","year":"2018","unstructured":"Ahlqvist E, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6(5):361\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"3097_CR25","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1210\/clinem\/dgab810","volume":"107","author":"N Saatmann","year":"2022","unstructured":"Saatmann N, et al. Physical fitness and cardiovascular risk factors in novel diabetes subgroups. J Clin Endocrinol Metab. 2022;107(4):1127\u201339.","journal-title":"J Clin Endocrinol Metab"},{"key":"3097_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev-nutr-071715-050656","volume":"36","author":"C Koliaki","year":"2016","unstructured":"Koliaki C, Roden M. Alterations of mitochondrial function and insulin sensitivity in human obesity and diabetes mellitus. Annu Rev Nutr. 2016;36:337\u201367.","journal-title":"Annu Rev Nutr"},{"issue":"1\u20132","key":"3097_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mce.2013.06.002","volume":"379","author":"C Koliaki","year":"2013","unstructured":"Koliaki C, Roden M. Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease. Mol Cell Endocrinol. 2013;379(1\u20132):35\u201342.","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"3097_CR28","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/j.1463-1326.2004.00439.x","volume":"7","author":"M Krebs","year":"2005","unstructured":"Krebs M, Roden M. Molecular mechanisms of lipid-induced insulin resistance in muscle, liver and vasculature. Diabetes Obes Metab. 2005;7(6):621\u201332.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"3097_CR29","doi-asserted-by":"publisher","first-page":"e13017","DOI":"10.1111\/eci.13017","volume":"48","author":"K Bodis","year":"2018","unstructured":"Bodis K, Roden M. Energy metabolism of white adipose tissue and insulin resistance in humans. Eur J Clin Invest. 2018;48(11):e13017.","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"3097_CR30","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1016\/S2468-2667(22)00006-8","volume":"7","author":"X Camacho","year":"2022","unstructured":"Camacho X, et al. Relative contribution of trends in myocardial infarction event rates and case fatality to declines in mortality: an international comparative study of 1.95 million events in 80.4 million people in four countries. Lancet Public Health. 2022;7(3):e229\u201339.","journal-title":"Lancet Public Health"},{"issue":"1","key":"3097_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41591-020-1116-9","volume":"27","author":"R Wagner","year":"2021","unstructured":"Wagner R, et al. Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med. 2021;27(1):49\u201357.","journal-title":"Nat Med"},{"issue":"9","key":"3097_CR32","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","volume":"7","author":"OP Zaharia","year":"2019","unstructured":"Zaharia OP, et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol. 2019;7(9):684\u201394.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"3097_CR33","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s00125-018-4568-4","volume":"61","author":"A Tura","year":"2018","unstructured":"Tura A, et al. Prediction of clamp-derived insulin sensitivity from the oral glucose insulin sensitivity index. Diabetologia. 2018;61(5):1135\u201341.","journal-title":"Diabetologia"},{"issue":"25","key":"3097_CR34","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1093\/eurheartj\/ehac191","volume":"43","author":"J Fischer","year":"2022","unstructured":"Fischer J, et al. Master switches in cardiac ischaemia: the collaborative research center (CRC) 1116 of the German Research Foundation. Eur Heart J. 2022;43(25):2350\u20131.","journal-title":"Eur Heart J"},{"issue":"1","key":"3097_CR35","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12872-023-03210-1","volume":"23","author":"F B\u00f6nner","year":"2023","unstructured":"B\u00f6nner F, et al. Systemi - systemic organ communication in STEMI: design and rationale of a cohort study of patients with ST-segment elevation myocardial infarction. BMC Cardiovasc Disord. 2023;23(1):232.","journal-title":"BMC Cardiovasc Disord"},{"issue":"20","key":"3097_CR36","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","volume":"138","author":"K Thygesen","year":"2018","unstructured":"Thygesen K, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138(20):e618\u201351.","journal-title":"Circulation"},{"key":"3097_CR37","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice, C., 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. Diabetes Care, 2025. 48(Supplement_1): p. S27-S49.","DOI":"10.2337\/dc25-S002"},{"issue":"10","key":"3097_CR38","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.2337\/dci21-0034","volume":"44","author":"MC Riddle","year":"2021","unstructured":"Riddle MC, et al. Consensus report: definition and interpretation of remission in Type 2 diabetes. Diabetes Care. 2021;44(10):2438\u201344.","journal-title":"Diabetes Care"},{"key":"3097_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0374-9","volume":"15","author":"J Szendroedi","year":"2016","unstructured":"Szendroedi J, et al. Cohort profile: the German Diabetes Study (GDS). Cardiovasc Diabetol. 2016;15:59.","journal-title":"Cardiovasc Diabetol"},{"key":"3097_CR40","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2337\/diacare.24.3.539","volume":"24","author":"A Mari","year":"2001","unstructured":"Mari A, et al. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care. 2001;24:539\u201348.","journal-title":"Diabetes Care"},{"issue":"3","key":"3097_CR41","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.metabol.2008.09.029","volume":"58","author":"DS Le","year":"2009","unstructured":"Le DS, et al. Repeatability and reproducibility of the hyperinsulinemic-euglycemic clamp and the tracer dilution technique in a controlled inpatient setting. Metabolism. 2009;58(3):304\u201310.","journal-title":"Metabolism"},{"issue":"1","key":"3097_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2337\/diabetes.51.1.49","volume":"51","author":"MG Bischof","year":"2002","unstructured":"Bischof MG, et al. Hepatic glycogen metabolism in type 1 diabetes after long-term near normoglycemia. Diabetes. 2002;51(1):49\u201354.","journal-title":"Diabetes"},{"issue":"6","key":"3097_CR43","doi-asserted-by":"publisher","first-page":"e39029","DOI":"10.1371\/journal.pone.0039029","volume":"7","author":"JG Hattersley","year":"2012","unstructured":"Hattersley JG, et al. Quantifying the improvement of surrogate indices of hepatic insulin resistance using complex measurement techniques. PLoS ONE. 2012;7(6):e39029.","journal-title":"PLoS ONE"},{"issue":"5","key":"3097_CR44","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.2047-6310.2013.00189.x","volume":"9","author":"MM Kelsey","year":"2014","unstructured":"Kelsey MM, et al. Adipose tissue insulin resistance in adolescents with and without type 2 diabetes. Pediatr Obes. 2014;9(5):373\u201380.","journal-title":"Pediatr Obes"},{"issue":"4","key":"3097_CR45","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1210\/jc.2017-00047","volume":"102","author":"E Sondergaard","year":"2017","unstructured":"Sondergaard E, et al. How to measure adipose tissue insulin sensitivity. J Clin Endocrinol Metab. 2017;102(4):1193\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"3097_CR46","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/hep.29302","volume":"66","author":"G Xiao","year":"2017","unstructured":"Xiao G, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66(5):1486\u2013501.","journal-title":"Hepatology"},{"key":"3097_CR47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1148\/radiol.10092284","volume":"257","author":"J Machann","year":"2010","unstructured":"Machann J, et al. Follow-up whole-body assessment of adipose tissue compartments during a lifestyle intervention in a large cohort at increased risk for type 2 diabetes. Radiology. 2010;257:353\u201363.","journal-title":"Radiology"},{"issue":"5","key":"3097_CR48","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/mrm.24835","volume":"71","author":"A Laufs","year":"2014","unstructured":"Laufs A, et al. Quantitative liver 31P magnetic resonance spectroscopy at 3T on a clinical scanner. Magn Reson Med. 2014;71(5):1670\u20135.","journal-title":"Magn Reson Med"},{"issue":"3","key":"3097_CR49","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/jmri.23731","volume":"37","author":"SK Venkatesh","year":"2013","unstructured":"Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging. 2013;37(3):544\u201355.","journal-title":"J Magn Reson Imaging"},{"key":"3097_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2024-004727","author":"Y Kupriyanova","year":"2025","unstructured":"Kupriyanova Y, et al. Alterations of hepatic lipid content following COVID-19 in persons with type 2 diabetes. BMJ Open Diabetes Res Care. 2025;13:e004727.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"10","key":"3097_CR51","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.2337\/db23-0353","volume":"72","author":"M Schon","year":"2023","unstructured":"Schon M, et al. Intramyocellular triglyceride content during the early course of type 1 and type 2 diabetes. Diabetes. 2023;72(10):1483\u201392.","journal-title":"Diabetes"},{"key":"3097_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12968-020-00607-1","author":"CM Kramer","year":"2020","unstructured":"Kramer CM, et al. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson. 2020;22:17.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"3097_CR53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12968-022-00846-4","volume":"24","author":"RH Davies","year":"2022","unstructured":"Davies RH, et al. Precision measurement of cardiac structure and function in cardiovascular magnetic resonance using machine learning. J Cardiovasc Magn Reson. 2022;24(1):16.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"3097_CR54","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/jmri.21837","volume":"30","author":"JR van Werven","year":"2009","unstructured":"van Werven JR, et al. Reproducibility of 3.0 Tesla magnetic resonance spectroscopy for measuring hepatic fat content. J Magn Reson Imaging. 2009;30(2):444\u20138.","journal-title":"J Magn Reson Imaging"},{"issue":"8","key":"3097_CR55","doi-asserted-by":"publisher","first-page":"e5120","DOI":"10.1002\/nbm.5120","volume":"37","author":"M Jonuscheit","year":"2024","unstructured":"Jonuscheit M, et al. Reproducibility of absolute quantification of adenosine triphosphate and inorganic phosphate in the liver with localized (31P)-magnetic resonance spectroscopy at 3-T using different coils. NMR Biomed. 2024;37(8):e5120.","journal-title":"NMR Biomed"},{"issue":"6","key":"3097_CR56","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes PJ, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717\u201330.","journal-title":"Gastroenterology"},{"issue":"4","key":"3097_CR57","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","volume":"17","author":"C Hsu","year":"2019","unstructured":"Hsu C, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2019;17(4):630-637 e8.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"3097_CR58","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.jhep.2022.08.010","volume":"77","author":"K Pafili","year":"2022","unstructured":"Pafili K, et al. Mitochondrial respiration is decreased in visceral but not subcutaneous adipose tissue in obese individuals with fatty liver disease. J Hepatol. 2022;77(6):1504\u201314.","journal-title":"J Hepatol"},{"issue":"1","key":"3097_CR59","doi-asserted-by":"publisher","first-page":"7056","DOI":"10.1038\/s41467-021-27153-3","volume":"12","author":"C Granata","year":"2021","unstructured":"Granata C, et al. High-intensity training induces non-stoichiometric changes in the mitochondrial proteome of human skeletal muscle without reorganisation of respiratory chain content. Nat Commun. 2021;12(1):7056.","journal-title":"Nat Commun"},{"key":"3097_CR60","doi-asserted-by":"publisher","first-page":"e12856","DOI":"10.7717\/peerj.12856","volume":"10","author":"J Kuang","year":"2022","unstructured":"Kuang J, et al. Interpretation of exercise-induced changes in human skeletal muscle mRNA expression depends on the timing of the post-exercise biopsies. PeerJ. 2022;10:e12856.","journal-title":"PeerJ"},{"issue":"4","key":"3097_CR61","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3945\/ajcn.112.035014","volume":"97","author":"P Schadewaldt","year":"2013","unstructured":"Schadewaldt P, et al. Indirect calorimetry in humans: a postcalorimetric evaluation procedure for correction of metabolic monitor variability. Am J Clin Nutr. 2013;97(4):763\u201373.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"3097_CR62","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s00125-020-05310-5","volume":"64","author":"D Ziegler","year":"2021","unstructured":"Ziegler D, et al. Association of cardiac autonomic dysfunction with higher levels of plasma lipid metabolites in recent-onset type 2 diabetes. Diabetologia. 2021;64(2):458\u201368.","journal-title":"Diabetologia"},{"key":"3097_CR63","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/j.1464-5491.1992.tb01898.x","volume":"9","author":"D Ziegler","year":"1992","unstructured":"Ziegler D, et al. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses at various stages of diabetic neuropathy. Diabet Med. 1992;9:806\u201314.","journal-title":"Diabet Med"},{"key":"3097_CR64","unstructured":"Bundes\u00e4rztekammer, Richtlinie der Bundes\u00e4rztekammer zur Qualit\u00e4tssicherung laboratoriumsmedizinischer Untersuchungen. Deutsches \u00c4rzteblatt Online, 2022."},{"issue":"2","key":"3097_CR65","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1210\/jc.2017-01706","volume":"103","author":"OP Zaharia","year":"2018","unstructured":"Zaharia OP, et al. Metabolic characteristics of recently diagnosed adult-onset autoimmune diabetes mellitus. J Clin Endocrinol Metab. 2018;103(2):429\u201337.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"3097_CR66","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.2337\/db20-1054","volume":"70","author":"C Herder","year":"2021","unstructured":"Herder C, et al. Differences in biomarkers of inflammation between novel subgroups of recent-onset diabetes. Diabetes. 2021;70(5):1198\u2013208.","journal-title":"Diabetes"},{"issue":"11","key":"3097_CR67","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.2337\/db18-0060","volume":"67","author":"C Herder","year":"2018","unstructured":"Herder C, et al. A systemic inflammatory signature reflecting cross talk between innate and adaptive immunity is associated with incident polyneuropathy: KORA F4\/FF4 study. Diabetes. 2018;67(11):2434\u201342.","journal-title":"Diabetes"},{"issue":"12","key":"3097_CR68","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3390\/metabo13121181","volume":"13","author":"D Bizzarri","year":"2023","unstructured":"Bizzarri D, et al. Technical report: a comprehensive comparison between different quantification versions of nightingale health\u2019s 1H-NMR metabolomics platform. Metabolites. 2023;13(12):1181.","journal-title":"Metabolites"},{"issue":"1","key":"3097_CR69","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41467-023-36231-7","volume":"14","author":"H Julkunen","year":"2023","unstructured":"Julkunen H, et al. Atlas of plasma NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank. Nat Commun. 2023;14(1):604.","journal-title":"Nat Commun"},{"key":"3097_CR70","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3389\/fgene.2015.00352","volume":"6","author":"J Baran-Gale","year":"2015","unstructured":"Baran-Gale J, et al. Addressing bias in small RNA library preparation for sequencing: a new protocol recovers microRNAs that evade capture by current methods. Front Genet. 2015;6:352.","journal-title":"Front Genet"},{"issue":"2","key":"3097_CR71","first-page":"334","volume":"2","author":"SD Anker","year":"2024","unstructured":"Anker SD, et al. Using multiple primary endpoints in clinical trials with a focus on heart failure. Glob Cardiol. 2024;2(2):334.","journal-title":"Glob Cardiol"},{"key":"3097_CR72","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-025-06486-4","author":"T Mori","year":"2025","unstructured":"Mori T, et al. Recognising, quantifying and accounting for classification uncertainty in type 2 diabetes subtypes. Diabetologia. 2025;68:2139\u20132150.","journal-title":"Diabetologia"},{"issue":"6","key":"3097_CR73","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1161\/CIRCIMAGING.112.974998","volume":"5","author":"I Eitel","year":"2012","unstructured":"Eitel I, et al. Prognostic impact of hyperglycemia in nondiabetic and diabetic patients with ST-elevation myocardial infarction: insights from contrast-enhanced magnetic resonance imaging. Circ Cardiovasc Imaging. 2012;5(6):708\u201318.","journal-title":"Circ Cardiovasc Imaging"},{"key":"3097_CR74","doi-asserted-by":"publisher","first-page":"1303685","DOI":"10.3389\/fcvm.2024.1303685","volume":"11","author":"AH Alkatiri","year":"2024","unstructured":"Alkatiri AH, et al. Stress hyperglycemia and poor outcomes in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis. Front Cardiovasc Med. 2024;11:1303685.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"3097_CR75","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13098-025-01738-0","volume":"17","author":"BF Garcia","year":"2025","unstructured":"Garcia BF, et al. Impact of elevated glucose levels on cardiac function in STEMI patients: glucose delta as a prognostic biomarker. Diabetol Metab Syndr. 2025;17(1):203.","journal-title":"Diabetol Metab Syndr"},{"issue":"12","key":"3097_CR76","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.metabol.2015.09.002","volume":"64","author":"K Kaul","year":"2015","unstructured":"Kaul K, Apostolopoulou M, Roden M. Insulin resistance in type 1 diabetes mellitus. Metabolism. 2015;64(12):1629\u201339.","journal-title":"Metabolism"},{"key":"3097_CR77","doi-asserted-by":"publisher","first-page":"101122","DOI":"10.1016\/j.molmet.2020.101122","volume":"50","author":"K Pafili","year":"2021","unstructured":"Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab. 2021;50:101122.","journal-title":"Mol Metab"},{"key":"3097_CR78","doi-asserted-by":"publisher","first-page":"154299","DOI":"10.1016\/j.metabol.2020.154299","volume":"111s","author":"B Dewidar","year":"2020","unstructured":"Dewidar B, et al. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism. 2020;111s:154299.","journal-title":"Metabolism"},{"key":"3097_CR79","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1172\/JCI118742","volume":"97","author":"M Roden","year":"1996","unstructured":"Roden M, et al. Mechanism of free fatty acid\u2013induced insulin resistance in humans. J Clin Invest. 1996;97:2859\u201365.","journal-title":"J Clin Invest"},{"issue":"10","key":"3097_CR80","doi-asserted-by":"publisher","first-page":"e4167","DOI":"10.1210\/clinem\/dgac480","volume":"107","author":"OP Zaharia","year":"2022","unstructured":"Zaharia OP, et al. Metabolic factors predict changes in endothelial function during the early course of type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2022;107(10):e4167\u201376.","journal-title":"J Clin Endocrinol Metab"},{"key":"3097_CR81","doi-asserted-by":"publisher","DOI":"10.2337\/dci25-0054","author":"R Wagner","year":"2025","unstructured":"Wagner R, et al. Beyond glucose-rethinking prediabetes for precision prevention. Diabetes Care. 2025;48:1\u201310.","journal-title":"Diabetes Care"},{"issue":"1","key":"3097_CR82","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12933-023-01923-3","volume":"22","author":"K Prystupa","year":"2023","unstructured":"Prystupa K, et al. Clusters of prediabetes and type 2 diabetes stratify all-cause mortality in a cohort of participants undergoing invasive coronary diagnostics. Cardiovasc Diabetol. 2023;22(1):211.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3097_CR83","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12933-021-01385-5","volume":"20","author":"A Natali","year":"2021","unstructured":"Natali A, et al. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence. Cardiovasc Diabetol. 2021;20(1):196.","journal-title":"Cardiovasc Diabetol"},{"key":"3097_CR84","doi-asserted-by":"publisher","first-page":"101032","DOI":"10.1016\/j.lanepe.2024.101032","volume":"45","author":"HC Ros\u00e9n","year":"2024","unstructured":"Ros\u00e9n HC, et al. SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART. Lancet Reg Health Eur. 2024;45:101032.","journal-title":"Lancet Reg Health Eur"},{"issue":"7","key":"3097_CR85","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","volume":"12","author":"MS Usman","year":"2024","unstructured":"Usman MS, et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2024;12(7):447\u201361.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"3097_CR86","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"3097_CR87","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve SV, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13(1):15\u201328.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"3097_CR88","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1038\/s41591-023-02502-5","volume":"29","author":"DK Tobias","year":"2023","unstructured":"Tobias DK, et al. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat Med. 2023;29(10):2438\u201357.","journal-title":"Nat Med"},{"issue":"1","key":"3097_CR89","doi-asserted-by":"publisher","first-page":"H125","DOI":"10.1152\/ajpheart.00172.2023","volume":"325","author":"C Eickelmann","year":"2023","unstructured":"Eickelmann C, et al. Mitochondrial respiration analysis in permeabilized porcine left ventricular and human right atrial specimens with ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2023;325(1):H125\u201335.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"3097_CR90","unstructured":"American Diabetes Association Professional Practice, C., 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabetes Care, 2025. 48(Supplement_1): p. S181-S206."},{"issue":"39","key":"3097_CR91","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"key":"3097_CR92","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes (EASD. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obesity Facts. 2024;17(4):374-444.","DOI":"10.1159\/000539371"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03097-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03097-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03097-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:10:17Z","timestamp":1774530617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03097-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3097"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03097-0","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The\n                      DISTEMI\n                      study is approved by the ethics committee of the Medical Faculty of Heinrich Heine University D\u00fcsseldorf (reference number: 2018-213-KFmgU, registry ID: 2018104839). All procedures were performed in line with the Declaration of Helsinki, current (2013) version. All participants of the\n                      DISTEMI\n                      study gave written informed consent prior to study inclusion.\n                      DISTEMI\n                      is registered at\n                      \n                      : NCT05046483.Ethics approval for animal tissue is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the funding sources play any role in the writing of the manuscript or the decision to submit it for publication or any aspect pertinent to the study. The authors declare no conflict of interest with regard to this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}